Clinical Trials for FutureGen Biopharmaceutical

Explore 2 clinical trials worldwide

Showing 1-2 of 2 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: FutureGen Biopharmaceutical

Clinical Trials (2)

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

PHASE3Recruiting

486 participants

Started: Dec 25, 2023 · Completed: Apr 11, 2027

2 conditions1 sponsor1 location

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

PHASE1Recruiting

152 participants

Started: Jun 11, 2021 · Completed: Dec 30, 2024

1 condition1 sponsor1 location